Inhibrx Biosciences

Robust Pipeline for Ewing Sarcoma Treatment: 25+ Companies Advancing Novel Therapies

3 months ago

• A comprehensive pipeline analysis reveals over 25 pharmaceutical companies actively developing treatments for Ewing Sarcoma, with multiple promising candidates in various clinical stages. • Gradalis's Vigil, a personalized cancer immunotherapy, has advanced to Phase III trials in combination with irinotecan and temozolomide for Ewing Sarcoma treatment. • Key emerging therapies include Oncternal's ONCT216, a first-in-class ETS-family transcription factor inhibitor, and Salarius's SP-2577, currently in Phase I/II trials for multiple sarcoma types.

Inhibrx's Ozekibart Shows Promise in Phase 1 Colorectal Cancer Trial

4 months ago

• Inhibrx Biosciences announced preliminary Phase 1 data for ozekibart (INBRX-109) combined with FOLFIRI in advanced colorectal adenocarcinoma, presented at ASCO GI Cancers Symposium. • The trial showed one complete response, three partial responses, and six cases of stable disease in 10 evaluable patients, with 46.2% achieving durable disease control. • Ozekibart-related adverse events were mostly low-grade, with the most common being nausea, increased alanine aminotransferase, diarrhea, and fatigue. • An expansion cohort enrolling up to 50 patients with 2-3 prior lines of therapy has been initiated to validate these findings, with data expected in Q3 2025.

I-Mab Announces Pipeline Progress and Financial Results for 1H 2024

9 months ago

• I-Mab completed the divestiture of its China operations, streamlining the organization and transitioning to a U.S.-based operating model. • Uliledlimab received IND clearance, paving the way for U.S. combination studies in first-line metastatic non-small cell lung cancer. • A clinical collaboration with Bristol Myers Squibb will strengthen givastomig combination studies for first-line gastric cancer. • Ragistomig's early data presented at ASCO 2024 highlighted encouraging objective responses in patients with advanced solid tumors.